(Q57598533)

Brian D. Robertson

1

0 references

Eric Rubin

Eric Rubin

21

0 references

Gerhard Walzl

Gerhard Walzl

26

0 references

Robert J. Wilkinson

Robert Wilkinson

28

0 references

Stefan Kaufmann

Stefan H.E. Kaufmann

17

0 references

Thomas Dick

Thomas Dick

6

0 references

Valerie Mizrahi

20

Valerie Mizrahi

0 references

William Bishai

4

Bill Bishai

0 references

Willem Albert Hanekom

14

Willem Hanekom

0 references

Digby F Warner

27

Digby Warner

0 references

Gilla Kaplan

16

Gilla Kaplan

0 references

Christopher Dye

8

Chris Dye

0 references

Dirk Schnappinger

22

Dirk Schnappinger

0 references

Sabine Ehrt

9

Sabine Ehrt

0 references

Paul van Helden

15

Paul van Helden

0 references

Christian Lienhardt

19

Christian Lienhardt

0 references

Stewart Cole

5

Stewart Cole

0 references

author name string

Danny Altmann

2

0 references

Clif Barry

3

0 references

Ken Duncan

7

0 references

JoAnne Flynn

11

0 references

Richard Hafner

12

0 references

Gray Handley

13

0 references

Peter Kim

18

0 references

David Sherman

23

0 references

Jelle Thole

24

0 references

Omar Vandal

25

0 references

Douglas Young

The population dynamics and control of tuberculosis

29

0 references

publication date

November 2012

0 references

published in

Tuberculosis

0 references

volume

92

0 references

issue

6

0 references

page(s)

447-452

0 references

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2012.06.004

What research is needed to stop TB? Introducing the TB Research Movement

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2012.06.004

The spectrum of latent tuberculosis: rethinking the biology and intervention strategies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2012.06.004

Three months of rifapentine and isoniazid for latent tuberculosis infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2012.06.004

Prevalence of tuberculosis, HIV and respiratory symptoms in two Zambian communities: implications for tuberculosis control in the era of HIV

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2012.06.004

Comparison of two active case-finding strategies for community-based diagnosis of symptomatic smear-positive tuberculosis and control of infectious tuberculosis in Harare, Zimbabwe (DETECTB): a cluster-randomised trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2012.06.004

National survey of tuberculosis prevalence in Viet Nam.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2012.06.004

High prevalence of subclinical tuberculosis in HIV-1-infected persons without advanced immunodeficiency: implications for TB screening

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2012.06.004

Human gene expression profiles of susceptibility and resistance in tuberculosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2012.06.004

An interferon-inducible neutrophil-driven blood transcriptional signature in human tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2012.06.004

Systems biology in immunology: a computational modeling perspective.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2012.06.004

The influence of bacille Calmette-Guerin vaccine strain on the immune response against tuberculosis: a randomized trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2012.06.004

Mycobacterium tuberculosis: success through dormancy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2012.06.004

Characterization and transcriptome analysis of Mycobacterium tuberculosis persisters

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2012.06.004

Cytological and transcript analyses reveal fat and lazy persister-like bacilli in tuberculous sputum

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2012.06.004

Transcriptional Adaptation of Mycobacterium tuberculosis within Macrophages: Insights into the Phagosomal Environment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2012.06.004

Neutrophils are the predominant infected phagocytic cells in the airways of patients with active pulmonary TB.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2012.06.004

The protonmotive force is required for maintaining ATP homeostasis and viability of hypoxic, nonreplicating Mycobacterium tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2012.06.004

A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2012.06.004

Pyrazinamide inhibits trans-translation in Mycobacterium tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2012.06.004

Delamanid for multidrug-resistant pulmonary tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2012.06.004

How antibacterials really work: impact on drug discovery.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2012.06.004

PA-824 kills nonreplicating Mycobacterium tuberculosis by intracellular NO release

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2012.06.004

Sterilizing activity of novel TMC207- and PA-824-containing regimens in a murine model of tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2012.06.004

Quantitative comparison of active and latent tuberculosis in the cynomolgus macaque model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2012.06.004

Additive effects of isoniazid preventive therapy and HAART.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2012.06.004

Tuberculosis-associated immune reconstitution inflammatory syndrome and unmasking of tuberculosis by antiretroviral therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2012.06.004

Dissection of regenerating T-Cell responses against tuberculosis in HIV-infected adults sensitized by Mycobacterium tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2012.06.004

Intracellular bacterial growth is controlled by a kinase network around PKB/AKT1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2012.06.004

Host genotype-specific therapies can optimize the inflammatory response to mycobacterial infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2012.06.004

Phosphodiesterase-4 inhibition alters gene expression and improves isoniazid-mediated clearance of Mycobacterium tuberculosis in rabbit lungs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2012.06.004

Future Vaccination Strategies against Tuberculosis: Thinking outside the Box

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2012.06.004

Taking a New Shot At a TB Vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2012.06.004

A multistage tuberculosis vaccine that confers efficient protection before and after exposure.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2012.06.004

Systems biology of persistent infection: tuberculosis as a case study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2012.06.004